2 Information about baricitinib

Marketing authorisation indication

2.1 Baricitinib (Olumiant, Eli Lilly and Company) is indicated for 'the treatment of severe alopecia areata in adult patients'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for baricitinib.


2.3 The list price of baricitinib is £805.56 for a 28‑tablet pack of either 2 mg or 4 mg tablets (excluding VAT, BNF online accessed October 2023).

2.4 The company has a commercial arrangement. This makes baricitinib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)